Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents

Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents

Abstract As more lupus nephritis (LN) medications become available, identifying treatments that are disease-modifying is critical in making treatment decisions. Based on our 2022 published working definition of LN disease modification as ‘minimizing disease activity with the fewest treatment-associa...

Full description

Saved in:
Bibliographic Details
Main Authors: Anca D. Askanase, Richard Furie, Maria Dall’Era, Andrew S. Bomback, Andreas Schwarting, Ming-Hui Zhao, Ian N. Bruce, Munther Khamashta, Bernard Rubin, Angela Carroll, Roger Abramino Levy, Ronald van Vollenhoven, Murray B. Urowitz
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Rheumatology and Therapy
Subjects:
Biological products
Glucocorticoids
Lupus erythematosus
Systemic
Lupus nephritis
Online Access:https://doi.org/10.1007/s40744-025-00752-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-025-00752-y

Similar Items